Kathmere Capital Management’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

Kathmere Capital Management’s Portfolio SXTP Stock Details SXTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$467K	Buy	265,100 +120,417	+83%	+$194K	0.02%	412
2026 Q1	$253K	Buy	+144,683	New	+$411K	0.02%	515

Other funds holding SXTP

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Kathmere Capital Management's SXTP Position: Q2 2026 in Review

Kathmere Capital Management increased its 60 Degrees Pharmaceuticals (SXTP) stake by 83% in Q2 2026, buying an estimated $194K and bringing the position to 265,100 shares worth $467K. The position accounts for 0.02% of the portfolio, ranked #412.

Kathmere Capital Management first reported a position in SXTP in Q1 2026 and has held it in 2 quarters since. 8 funds tracked by Wall St. Rank hold SXTP as of Q2 2026.

Kathmere Capital Management held 265,100 shares of 60 Degrees Pharmaceuticals worth $467K as of Q2 2026.
Kathmere Capital Management bought 120,417 60 Degrees Pharmaceuticals shares in Q2 2026, an estimated $194K.
60 Degrees Pharmaceuticals made up 0.02% of Kathmere Capital Management's portfolio in Q2 2026, its #412 holding.
Kathmere Capital Management first reported a position in 60 Degrees Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
8 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q2 2026.

Based on Kathmere Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.